Percheron Therapeutics Raises $2.2 Million to Advance VISTA-Targeting Cancer Therapy HMBD-002
核心洞察
Percheron Therapeutics (搜索) announced a $2.2 million entitlement offer to fund development of HMBD-002, a monoclonal antibody targeting the VISTA (搜索) immune checkpoint regulator.
HMBD-002 has completed a phase I clinical trial in advanced cancer patients, demonstrating general safety and tolerability profiles.
The company plans to commence additional clinical trials for HMBD-002 in 2026 following the successful fundraising effort.
Percheron Therapeutics (搜索) Limited (ASX:PER) has announced a non-renounceable entitlement offer to raise approximately $2.2 million before costs, with proceeds primarily directed toward advancing development of its lead oncology asset HMBD-002. The biotechnology company, which focuses on novel therapies for oncology and rare diseases, detailed the offering in a prospectus lodged with ASIC on March 16, 2026.
Funding Structure and Terms
The entitlement offer provides eligible shareholders the opportunity to purchase two new fully paid ordinary shares for every five existing shares held, priced at $0.005 per new share. This pricing represents approximately a 20% discount to the 5-day volume weighted average price prior to the announcement.
Participants will receive additional incentives through one free attaching option for every two new shares subscribed. These options carry an exercise price of $0.01 each and expire two years from the date of issue. Any unsubscribed shares and options will be made available through a separate shortfall offer, with eligible shareholders who fully subscribe for their entitlement able to apply for additional securities.
HMBD-002 Development Program
The raised capital will primarily support progression of HMBD-002, a monoclonal antibody targeting VISTA (搜索), an immune checkpoint regulator. The therapeutic candidate has completed a phase I clinical trial in patients with advanced cancer, demonstrating that the drug is generally safe and well-tolerated.
Following the successful completion of initial safety studies, Percheron aims to commence further clinical trials for HMBD-002 in calendar year 2026. The VISTA (搜索) pathway represents a significant target in immuno-oncology, as immune checkpoint regulators play crucial roles in modulating anti-tumor immune responses.
Timeline and Management
The entitlement offer and shortfall offer are scheduled to close at 5:00 pm (AEST) on Wednesday, April 8, 2026, unless extended. Blue Ocean Equities (搜索) and Cygnet Capital (搜索) serve as lead managers for the offering, which is not underwritten.
Beyond HMBD-002 development, the funds will support general working capital requirements, including expenses associated with both the entitlement and shortfall offers. The company has encouraged eligible shareholders to carefully review the prospectus for detailed participation instructions and terms.